Evidence map›Paper›PMID 37955007›Full record

ArticleFrontiers in endocrinology2023

Deep neural network for discovering metabolism-related biomarkers for lung adenocarcinoma.

Lei Fu, Manshi Li, Junjie Lv, Chengcheng Yang, Zihan Zhang, Shimei Qin, Wan Li, Xinyan Wang, Lina Chen

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lei Fu *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Manshi Li *Department of Radiation Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.
Junjie Lv *College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Chengcheng Yang *Department of Respiratory, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Zihan ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Shimei QinCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Wan LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xinyan WangDepartment of Respiratory, Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Lina ChenCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Harbin Medical University · CNFourth Affiliated Hospital of China Medical University · CNSecond Affiliated Hospital of Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Lung cancer is a major cause of illness and death worldwide. Lung adenocarcinoma (LUAD) is its most common subtype. Metabolite-mRNA interactions play a crucial role in cancer metabolism. Thus, metabolism-related mRNAs are potential targets for cancer therapy. Methods: This study constructed a network of metabolite-mRNA interactions (MMIs) using four databases. We retrieved mRNAs from the Tumor Genome Atlas (TCGA)-LUAD cohort showing significant expressional changes between tumor and non-tumor tissues and identified metabolism-related differential expression (DE) mRNAs among the MMIs. Candidate mRNAs showing significant contributions to the deep neural network (DNN) model were mined. Using MMIs and the results of function analysis, we created a subnetwork comprising candidate mRNAs and metabolites. Results: Finally, 10 biomarkers were obtained after survival analysis and validation. Their good prognostic value in LUAD was validated in independent datasets. Their effectiveness was confirmed in the TCGA and an independent Clinical Proteomic Tumor Analysis Consortium (CPTAC) dataset by comparison with traditional machine-learning models. Conclusion: To summarize, 10 metabolism-related biomarkers were identified, and their prognostic value was confirmed successfully through the MMI network and the DNN model. Our strategy bears implications to pave the way for investigating metabolic biomarkers in other cancers.

Indexed as

Adenocarcinoma of LungLung NeoplasmsBiomarkersHumansProteomicsRNA, MessengerBiomarkersRNA, Messengerbiomarkersdeep neural networklung adenocarcinomametabolite-mRNA interactions networkrisk model

Identifiers

PMID37955007
PMCPMC10634586
OpenAlexW4388197270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.